How were Dova Pharmaceuticals' earnings last quarter?

Dova Pharmaceuticals Inc (NASDAQ:DOVA) announced its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by $0.03. The business had revenue of $3.52 million for the quarter, compared to analyst estimates of $5.63 million. Dova Pharmaceuticals had a negative net margin of 544.09% and a negative trailing twelve-month return on equity of 101.60%.

What other stocks do shareholders of Dova Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dova Pharmaceuticals investors own include Global Blood Therapeutics (GBT) , Aldeyra Therapeutics (ALDX) , Tesaro (TSRO) , Allena Pharmaceuticals (ALNA) , TherapeuticsMD (TXMD) , Viking Therapeutics (VKTX) , Ardelyx (ARDX) , Fate Therapeutics (FATE) , Galectin Therapeutics (GALT) and Heron Therapeutics (HRTX) .

When did Dova Pharmaceuticals IPO?

Dova Pharmaceuticals (DOVA) raised $66 million in an IPO on Thursday, June 29th 2017. The company issued 4,100,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners acted as the underwriters for the IPO.

NASDAQ:DOVA

Dova Pharmaceuticals (DOVA) Stock Price, News & Analysis

→ A.I. Pioneer Issues Urgent Warning to Americans (From TradeSmith) (Ad)

Free DOVA Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $28.04
▼
$28.04
50-Day Range: $28.04
▼
$28.04
52-Week Range: $5.62
▼
$28.54

Volume: 35,036 shs
Average Volume: 499,313 shs
Market Capitalization: $807.55 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Dova Pharmaceuticals alerts:

Ad TradeSmith

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

Click here to see Louis' new video for yourself.

About Dova Pharmaceuticals Stock (NASDAQ:DOVA)

Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. It also develops DOPTELET for the treatment of chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina.

Ad TradeSmith

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

Click here to see Louis' new video for yourself.

DOVA Stock News Headlines

March 7, 2024 | uk.finance.yahoo.com

Analysis of Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology Signed During 2016-2024

August 22, 2023 | bizjournals.com

Fulcrum swings back up after FDA lifts clinical hold

April 18, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

May 15, 2023 | technews.tmcnet.com

Fulcrum Therapeutics Appoints Alex C. Sapir Chief Executive Officer

March 29, 2023 | marketwatch.com

Immune Thrombocytopenia Market 2023 Size to reach USD 3.33 Billion by 2026 With A 0.54% CAGR

March 21, 2023 | marketwatch.com

With A 0.54% CAGR, Immune Thrombocytopenia Market 2023 Size Will Reach USD 3.33 Billion by 2026

February 27, 2023 | marketwatch.com

Latest Research on Chemotherapy Induced Thrombocytopenia Drugs Market Report 2023-2029

February 19, 2023 | marketwatch.com

Global Immune Thrombocytopenia Treatment Market Size To Grow On The Basis Of Refined Innovation From 2023-2030 By VMReports

April 18, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

September 20, 2022 | finance.yahoo.com

Pasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J. Novak to its Board of Directors

September 14, 2022 | investing.com

Tethys Oil AB (TETY)

August 11, 2022 | fool.com

Molina Healthcare (NYSE: MOH)

July 23, 2022 | uk.news.yahoo.com

UK watchdog fines Pfizer, Flynn Pharma $84 million for overcharging NHS

July 19, 2022 | marketwatch.com

Global Immune Thrombocytopenia Market to Rise at 0.54% CAGR from 2019-2026

June 9, 2022 | investing.com

DOVA_old Historical Data

April 30, 2022 | uk.finance.yahoo.com

'This is not pressure' - Passionate Parker issues rallying cry ahead of huge Blackburn clash

April 30, 2022 | reuters.com

Ukraine Holocaust survivors find shelter in Israel

March 24, 2022 | marketwatch.com

Immune Thrombocytopenia (ITP) Market Research Update, Size Estimation, Future Scope, Revenue Opportunities and Regional Forecast to 2028

November 9, 2021 | benzinga.com

Verona Pharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update

September 2, 2021 | marketwatch.com

Advent, GIC Affiliate Launch $8.1 Bln Takeover Bid for Sweden's Sobi

See More Headlines

Receive DOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dova Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/06/2019
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:DOVA
CUSIP: N/A
CIK: 1685071
Web: www.dova.com
Phone: 919-748-5975
Fax: N/A
Employees: 115
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.60)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-72,280,000.00
Net Margins: -544.09%
Pretax Margin: N/A
Return on Equity: -101.60%
Return on Assets: -67.21%

Debt

Debt-to-Equity Ratio: 0.41
Current Ratio: 5.64
Quick Ratio: 5.37

Sales & Book Value

Annual Sales: $10.35 million
Price / Sales: 78.02
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.71 per share
Price / Book: 10.35

Miscellaneous

Outstanding Shares: 28,800,000
Free Float: N/A
Market Cap: $807.55 million
Optionable: Optionable
Beta: 2.74

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. David S. Zaccardelli (Age 54)
Pres & CEO
Mr. Mark W. Hahn (Age 56)
CFO & Sec.
Mr. Kevin Laliberte (Age 41)
Sr. VP of Product Devel.
Mr. Jason Levine
VP of Marketing
Mr. Ilija Zlatar
Head of U.S. Sales

Key Competitors

View All Competitors

DOVA Stock Analysis - Frequently Asked Questions

How were Dova Pharmaceuticals' earnings last quarter?: Dova Pharmaceuticals Inc (NASDAQ:DOVA) announced its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by $0.03. The business had revenue of $3.52 million for the quarter, compared to analyst estimates of $5.63 million. Dova Pharmaceuticals had a negative net margin of 544.09% and a negative trailing twelve-month return on equity of 101.60%.
What other stocks do shareholders of Dova Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Dova Pharmaceuticals investors own include Global Blood Therapeutics (GBT), Aldeyra Therapeutics (ALDX), Tesaro (TSRO), Allena Pharmaceuticals (ALNA), TherapeuticsMD (TXMD), Viking Therapeutics (VKTX), Ardelyx (ARDX), Fate Therapeutics (FATE), Galectin Therapeutics (GALT) and Heron Therapeutics (HRTX).
When did Dova Pharmaceuticals IPO?: Dova Pharmaceuticals (DOVA) raised $66 million in an IPO on Thursday, June 29th 2017. The company issued 4,100,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners acted as the underwriters for the IPO.

This page (NASDAQ:DOVA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Dova Pharmaceuticals (DOVA) Stock Price, News & Analysis

About Dova Pharmaceuticals Stock (NASDAQ:DOVA)

DOVA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

DOVA Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info